SCHEMBL5015533

SCHEMBL5015533

CCOC(=O)C(Cc1ccc(OCCBr)cc1)OCC

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 0.56
PPARG P37231 15/20 0.55
PPARD Q03181 6/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6387457 1.00 PPARA (0.56) PPARAPPARGPPARD
SCHEMBL4344001 0.91 PPARA (0.54) PPARAPPARGPPARD
SCHEMBL5382747 0.89 PPARA (0.51) PPARAPPARGPPARD
SCHEMBL4758451 0.88 PPARA (0.57) PPARAPPARGPPARD
SCHEMBL4758419 0.88 PPARA (0.57) PPARAPPARGPPARD
SCHEMBL5074787 0.88 PPARA (0.72) PPARAPPARGPPARD
SCHEMBL4755574 0.88 PPARA (0.57) PPARAPPARGPPARD
SCHEMBL4338075 0.88 PPARA (0.72) PPARAPPARGPPARD
SCHEMBL11932217 0.86 PPARA (0.56) PPARAPPARGPPARD
SCHEMBL5978209 0.86 PPARA (0.56) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939988-B1 Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2005-09-06 US claimed
US-7456293-B2 Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use SK HOLDING CO., LTD (KR) 2008-11-25 US disclosed
US-7456293-B2 Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use SK HOLDING CO., LTD (KR) 2008-11-25 US disclosed
US-7456293-B2 Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use SK HOLDING CO., LTD (KR) 2008-11-25 US disclosed
EP-1869004-A1 SUBSTITUTED CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS, THEIR PREPARATION AND USE SK Holdings Co., Ltd. (KR) 2007-12-26 EP disclosed
US-7157581-B2 Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2007-01-02 US disclosed
US-20060281802-A1 Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-12-14 US disclosed
US-7119198-B2 Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION (IN) 2006-10-10 US disclosed
WO-2006104349-A1 SUBSTITUTED CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS, THEIR PREPARATION AND USE SK HOLDINGS CO., LTD. (KR) 2006-10-05 WO disclosed
US-20060148793-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them REDDYS'S RESEARCH FOUNDATION 2006-07-06 US disclosed
EP-1049684-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-11-08 EP disclosed
US-6130214-A Benzothiazin and benzoxazin derivatives; their preparation and uses DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-10-10 US disclosed
WO-2000050414-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM DR.REDDY'S RESEARCH FOUNDATION (IN) 2000-08-31 WO disclosed
WO-2000023417-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed
WO-2000023416-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed
US-6054453-A HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. REDD'S RESEARCH FOUNDATION (IN) 2000-04-25 US disclosed
WO-1999038850-A1 NOVEL ALKANOIC ACIDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-08-05 WO disclosed
WO-1999019313-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-22 WO disclosed
WO-1999016758-A1 NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-08 WO disclosed
WO-1999008501-A2 NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281802-A1 Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use SLC5A1, CPT1A, GPR119 PPARA 174/4885PPARG 166/4885PPARD 196/4885
US-20060148793-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them LIPC, GPR119, CPT1A PPARA 209/4885PPARG 73/4885PPARD 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.